All News
NEJM Review - Glucocorticoid-Induced Osteoporosis
Lenore Buckley and Mary Humphrey have published a nice review of glucocorticoid-induced osteoporosis (GIOP) in the NEJM.
Read Article
Combo RA Treatment May Boost Risk for Serious Adverse Events
A current meta-analysis of safety and efficacy of combination bDMARD treatment in RA patients shows that combination treatments increase serious advese event (SAE) risks, and the risk for serious infections in particular.
Read Article
RheumNow Podcast – A Grand New Year (1.4.19)
Dr. Jack Cush reviews the news and journals for the beginning of 2019. All from RheumNow.com.
Best wishes for a charmed 2019! My advice: 1. Just show up. 2. If you can, then you must do. 3. Live each day as if it twas your 1st day/last day/make or break day. 4. Teach.
RheumNow Podcast – Rheumatologist Salaries (12.21.18)
Dr. Jack Cush reviews the news from RheumNow for the week ending 12/21/18.
Read Article
RheumNow Podcast – To Needle or Not to Needle (11.30.18)
Dr. Jack Cush updates the news and reports from the past week at RheumNow.com:
Read Article
The RheumNow Podcast – Heartbreak of Methotrexate (11.16.18)
Dr. Jack Cush reviews the news from the past week at RheumNow.com.
Read Article
Pilot Data on Rituximab in Henoch-Schonlein Purpura
Management of Henoch-Schonlein purpura (HSP) can be challenging as supportive care and avoidance of corticosteroids are often insufficient options. A new series of case reports and literature review of steroid refractory HSP suggests that rituximab may be effective in reducing hospital admissions, overall steroid use, and is capable of inducing remission.
Read Article
Excess Mortality in CTD or Systemic Vasculitis Patients
The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.
Read Article
The RheumNow Week in Review – We’re Number One! (8.17.18)
Dr. Cush reviews the articles and news from the last week on RheumNow.com. Information on comorbidities, the downside of steroids, unmet need in psoriatic arthritis, and the top 10 rheumatology programs.
Read Article
The RheumNow Week in Review – No Good Gout (8.10.18)
Dr. Jack Cush reviews the news and latest journal articles from the past week on RheumNow.com. Info on Surgery and Hip Fractures, Gout drugs abandoned, Allopurinol escalation, hydroxychloroquine drug levels, how to treat scleroderma in India and exactly who gets back pain.
Read Article
Opioid Aversion is Augmenting Spinal Steroid Injections
As physicians turn away from opioids, are they resorting to options that may also be unsafe?
The New York Times reports that some physicians are using the anti-inflammatory drug, Depo-Medrol, for intraspinal injections to manage painful spinal and perispinal disorders.
Read Article
Latin American Clinical Practice Guidelines for Lupus
The Annals of Rheumatic Disease have published the recently developed Latin American clinical practice guidelines for systemic lupus erythematosus (SLE) addressing the best pharmacologic interventions for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, hemat
Read Article
Steroids vs. NSAIDs in Treating Acute Gout
Gout, the ancient disease of kings is usually treated with the ancient (and costly) drug colchicine, often without consideration of nonsteroidal antiinflammatory drugs (NSAID) or corticosteroids.
Read Article
Best of 2017: New EULAR Guidelines on Behçet's
At the EULAR 2016 meeting, new EULAR recommendations for the management of Behçet's disease (BD) were presented.
Read Article
EULAR 2018 - Day 4 Report
The EULAR 2018 wound down on Saturday with fewer oral presentations but many posters. In my last report I put together a collection of impressions and some thematic highlights not covered in previous reports.
Read Article
Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)
Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.
Read Article
JAK Inhibition in Autoinflammatory Syndromes Interferonopathies
While many autoinflammatory syndromes are driven and managed with select inhibition of IL-1, IL-18 or IL-6, a subset are driven by type I interferon and are referred to as interferonopathies. These monogenic IFN–mediated disorders present in infancy with fevers, systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality.
Read Article
Risk of Psoriasis Complicating TNF Inhibitor Therapy
A population-based study of claims data from Korea shows that among inflammatory bowel disease (IBD) patients receiving tumour necrosis factor inhibitors (TNFi) there is a 3.7 per 100 patient-year risk of paradoxically developing psoriasis - a rate that is roughly 3-fold higher than risk in TNFi-naive IBD patients.
Read Article
The RheumNow Week in Review – Good News for GPA, CZP, Tofa but not ERA (6.1.18)
Dr. Jack Cush reviews this weeks reports from RheumNow.com, including the risk of autoimmunity with vaccination, early RA outcomes, new FDA approvals for certolizumab and tofacitinib and the risk of death from infection with biologics.
Read Article